La rosuvastatina: aspetti farmacologici.

Translated title of the contribution: Rosuvastatin: pharmacologic features

Franco Bernini, Alberico L. Catapano

Research output: Contribution to journalArticle

Abstract

The development of more active and safe new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) will increase the armamentarium of therapeutic tools available to the physicians for antiatherosclerotic therapies. Rosuvastatin presents a promising pharmacological profile: high affinity for the enzyme, a relative high hydrophilicity, selective hepatic uptake and activity, minimal cytochrome P450-mediated metabolism. Clinically the drug displays the highest lipid-lowering efficacy in the class with a safety profile similar to the other statins. Drug interaction potential is reduced. Rosuvastatin effectively decreases triglycerides, triglyceride-rich lipoproteins, non-HDL cholesterol, and increases HDL cholesterol. All together these properties will favor the achievement of therapeutic goals in the treated patients.

Original languageItalian
JournalItalian Heart Journal
Volume4 Suppl 7
Publication statusPublished - Dec 2003

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Triglycerides
HDL Lipoproteins
Hydrophobic and Hydrophilic Interactions
Drug Interactions
Cytochrome P-450 Enzyme System
HDL Cholesterol
Oxidoreductases
Therapeutics
Cholesterol
Pharmacology
Physicians
Lipids
Safety
Liver
Enzymes
Pharmaceutical Preparations
Rosuvastatin Calcium
3-hydroxy-3-methylglutaryl-coenzyme A

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

La rosuvastatina : aspetti farmacologici. / Bernini, Franco; Catapano, Alberico L.

In: Italian Heart Journal, Vol. 4 Suppl 7, 12.2003.

Research output: Contribution to journalArticle

@article{b2d8ecd2a85e4377afea880d378506fd,
title = "La rosuvastatina: aspetti farmacologici.",
abstract = "The development of more active and safe new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) will increase the armamentarium of therapeutic tools available to the physicians for antiatherosclerotic therapies. Rosuvastatin presents a promising pharmacological profile: high affinity for the enzyme, a relative high hydrophilicity, selective hepatic uptake and activity, minimal cytochrome P450-mediated metabolism. Clinically the drug displays the highest lipid-lowering efficacy in the class with a safety profile similar to the other statins. Drug interaction potential is reduced. Rosuvastatin effectively decreases triglycerides, triglyceride-rich lipoproteins, non-HDL cholesterol, and increases HDL cholesterol. All together these properties will favor the achievement of therapeutic goals in the treated patients.",
author = "Franco Bernini and Catapano, {Alberico L.}",
year = "2003",
month = "12",
language = "Italian",
volume = "4 Suppl 7",
journal = "Italian Heart Journal",
issn = "1129-471X",
publisher = "Societa Italiana di Cardiologia",

}

TY - JOUR

T1 - La rosuvastatina

T2 - aspetti farmacologici.

AU - Bernini, Franco

AU - Catapano, Alberico L.

PY - 2003/12

Y1 - 2003/12

N2 - The development of more active and safe new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) will increase the armamentarium of therapeutic tools available to the physicians for antiatherosclerotic therapies. Rosuvastatin presents a promising pharmacological profile: high affinity for the enzyme, a relative high hydrophilicity, selective hepatic uptake and activity, minimal cytochrome P450-mediated metabolism. Clinically the drug displays the highest lipid-lowering efficacy in the class with a safety profile similar to the other statins. Drug interaction potential is reduced. Rosuvastatin effectively decreases triglycerides, triglyceride-rich lipoproteins, non-HDL cholesterol, and increases HDL cholesterol. All together these properties will favor the achievement of therapeutic goals in the treated patients.

AB - The development of more active and safe new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) will increase the armamentarium of therapeutic tools available to the physicians for antiatherosclerotic therapies. Rosuvastatin presents a promising pharmacological profile: high affinity for the enzyme, a relative high hydrophilicity, selective hepatic uptake and activity, minimal cytochrome P450-mediated metabolism. Clinically the drug displays the highest lipid-lowering efficacy in the class with a safety profile similar to the other statins. Drug interaction potential is reduced. Rosuvastatin effectively decreases triglycerides, triglyceride-rich lipoproteins, non-HDL cholesterol, and increases HDL cholesterol. All together these properties will favor the achievement of therapeutic goals in the treated patients.

UR - http://www.scopus.com/inward/record.url?scp=2342580159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342580159&partnerID=8YFLogxK

M3 - Articolo

C2 - 14983744

AN - SCOPUS:2342580159

VL - 4 Suppl 7

JO - Italian Heart Journal

JF - Italian Heart Journal

SN - 1129-471X

ER -